Get the Stockscreener App
8.31
0.72%
-0.06
Pre-market:
8.39
0.08
+0.96%
Nuvation Bio Inc stock is traded at $8.31, with a volume of 7.24M.
It is down -0.72% in the last 24 hours and up +72.05% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$8.37
Open:
$8.3
24h Volume:
7.24M
Relative Volume:
0.80
Market Cap:
$2.85B
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-23.74
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
+3.75%
1M Performance:
+72.05%
6M Performance:
+239.18%
1Y Performance:
+202.18%
1-Day Range:
$8.11
$8.565
1-Week Range:
$7.455
$8.565
52-Week Range:
$1.54
$8.565
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
8.31 | 2.87B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Will Nuvation Bio Inc. Warrants stock profit from AI boom2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 150,000 Shares of Stock - MarketBeat
Why millennials buy Nuvation Bio Inc. Warrants stockJuly 2025 Summary & Risk Managed Investment Signals - Newser
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result - Insider Monkey
Nuvation Bio (NYSE:NUVB) Stock Price Up 8.9%Still a Buy? - MarketBeat
Nuvation Bio’s chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
Nuvation Bio (NYSE:NUVB) Hits New 1-Year HighHere's What Happened - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will Nuvation Bio Inc. Class stock profit from AI boomJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser
10 Stocks Stealing Market Spotlight - Insider Monkey
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology - Investing News Network
Nuvation Bio’s Surge: Buy or Observe? - StocksToTrade
Nuvation Bio’s chief medical officer sells $1.17 million in stock - Investing.com
Nuvation Bio Insider Sold Shares Worth $1,173,255, According to a Recent SEC Filing - marketscreener.com
Nuvation Bio stock hits 52-week high at $8.24 - Investing.com
NUVB: Iptrozi and Safusidenib show strong clinical and commercial momentum, driving major growth potential - TradingView
NUVB: Iptrozi and Safusidenib drive strong growth, with robust financials and pipeline innovation - TradingView
Nuvation Bio: Phase 2 study results in IDH1-mutant gliomas published - Traders Union
Will Nuvation Bio Inc. Warrants stock benefit from sector leadershipWeekly Loss Report & Real-Time Volume Analysis - Newser
Geode Capital Management LLC Acquires 864,194 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Will Nuvation Bio Inc. Class stock outperform benchmarks2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Can Nuvation Bio Inc. Class stock surprise markets with earningsPortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
Why Nuvation Bio Inc. Class stock is a strong analyst pickExit Point & Fast Gaining Stock Strategy Reports - Newser
Is Nuvation Bio Inc. stock a safe buy before earningsTreasury Yields & AI Enhanced Market Trend Forecasts - Newser
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target - Investing.com Canada
HC Wainwright & Co. Reiterates Nuvation Bio (NUVB) Buy Recommendation - Nasdaq
What is Wedbush's Estimate for Nuvation Bio FY2027 Earnings? - MarketBeat
Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
Nuvation Bio: A Strong Company Now Fairly Priced - Seeking Alpha
Top Growth Companies With Strong Insider Ownership November 2025 - simplywall.st
Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? - Yahoo Finance
Nuvation Bio Outpaces Revenue Forecasts With IBTROZI Launch - Finimize
Nuvation Bio (NUVB): Exploring Valuation After a 52% One-Month Rally - Yahoo Finance
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 10,000 Shares of Stock - MarketBeat
Nuvation Bio to discontinue development of NUV-1511 - MSN
Nuvation Bio to Participate in Upcoming December 2025 Investor Conferences - BioSpace
Nuvation Bio officer Liu sells $155k in shares By Investing.com - Investing.com Nigeria
Nuvation Bio officer Liu sells $155k in shares - Investing.com
Nuvation Bio's Chief Medical Officer Sells 20,000 Shares - TradingView
Nuvation Bio executives to join Evercore and Citi conferences - Traders Union
Officer Liu Files To Sell 10,000 Of Nuvation Bio Inc [NUVB] - TradingView
Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
Nuvation Bio stock hits 52-week high at 8.09 USD By Investing.com - Investing.com India
Nuvation Bio stock hits 52-week high at 8.09 USD - Investing.com
Nuvation Bio Inc Discontinues NUV-1511 Development - TradingView
Nuvation Bio’s Q3 2025: Clinical Progress and Financial Highlights - MSN
Nuvation Bio Insider Sold Shares Worth $2,667,132, According to a Recent SEC Filing - MarketScreener
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):